Literature DB >> 20561698

Development of a patient-reported questionnaire for collecting toxicity data following prostate brachytherapy.

Damian J J Farnell1, Paula Mandall, Carmel Anandadas, Jaqueline Routledge, Meriel P Burns, John P Logue, James P Wylie, Ric Swindell, Jac Livsey, Catharine M L West, Susan E Davidson.   

Abstract

PURPOSE: To improve a questionnaire used to collect patient-reported outcomes from patients with early stage prostate cancer treated with brachytherapy. A secondary aim was to adapt the Late Effects of Normal Tissue (LENT) subjective toxicity questionnaire for use to collect Common Terminology Criteria for Adverse Events (CTCAE) data, the current preferred platform for assessing radiation toxicity.
MATERIALS AND METHODS: Three hundred and seventy-seven patients were treated with permanent iodine-125 seed implant brachytherapy for early prostate cancer. Toxicity data were collected before and at nine time points post-treatment (0-36 months). Compliance rates for patients completing individual items and item-subsection correlation coefficients were calculated. A factor analysis was carried out to analyse responses to the questionnaire and identify less informative questions, which could be removed. Cronbach's α coefficient was used to measure reliability.
RESULTS: Two thousand one hundred and eighty-eight questionnaires were analysed. There was poor compliance for questions specifically relating to operations and bowel medication. We found that the division of the questionnaire into subsections based on anatomical site was reasonable and that certain items could be safely removed. The high mean value for Cronbach's α across all questionnaires (0.752; 95% CI: 0.726-0.779) indicated that the questionnaire was reliable. Fifteen of the 44 questions were removed from the original questionnaires. Questions on urinary incontinence severity, management of urinary and bowel incontinence, effects of reduced flow of urine and the effects of symptoms on activity of daily living and change in sexual function were required to adapt the LENT subjective questionnaire for use to collect CTCAE data.
CONCLUSIONS: A questionnaire, validated over 6 years to collect LENT subjective data were adapted and is a reliable approach for collecting CTCAE data after prostate brachytherapy.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20561698     DOI: 10.1016/j.radonc.2010.05.011

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  9 in total

1.  Radiation Dose to the Penile Structures and Patient-Reported Sexual Dysfunction in Long-Term Prostate Cancer Survivors.

Authors:  Maria Thor; Caroline E Olsson; Jung Hun Oh; David Alsadius; Niclas Pettersson; Joseph O Deasy; Gunnar Steineck
Journal:  J Sex Med       Date:  2015-11-13       Impact factor: 3.802

2.  A Factor Analysis Approach for Clustering Patient Reported Outcomes.

Authors:  Jung Hun Oh; Maria Thor; Caroline Olsson; Viktor Skokic; Rebecka Jörnsten; David Alsadius; Niclas Pettersson; Gunnar Steineck; Joseph O Deasy
Journal:  Methods Inf Med       Date:  2016-09-02       Impact factor: 2.176

3.  Temporal patterns of patient-reported trismus and associated mouth-opening distances in radiotherapy for head and neck cancer: A prospective cohort study.

Authors:  M Thor; C E Olsson; J H Oh; J Hedström; N Pauli; M Johansson; J O Deasy; C Finizia
Journal:  Clin Otolaryngol       Date:  2017-05-29       Impact factor: 2.597

4.  Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Jennifer L Hay; Thomas M Atkinson; Bryce B Reeve; Sandra A Mitchell; Tito R Mendoza; Gordon Willis; Lori M Minasian; Steven B Clauser; Andrea Denicoff; Ann O'Mara; Alice Chen; Antonia V Bennett; Diane B Paul; Joshua Gagne; Lauren Rogak; Laura Sit; Vish Viswanath; Deborah Schrag; Ethan Basch
Journal:  Qual Life Res       Date:  2013-07-20       Impact factor: 4.147

Review 5.  Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials.

Authors:  Ronald C Chen; Peter Chang; Richard J Vetter; Himansu Lukka; William A Stokes; Martin G Sanda; Deborah Watkins-Bruner; Bryce B Reeve; Howard M Sandler
Journal:  J Natl Cancer Inst       Date:  2014-07-08       Impact factor: 13.506

6.  Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study.

Authors:  N F Khan; D Mant; L Carpenter; D Forman; P W Rose
Journal:  Br J Cancer       Date:  2011-11-08       Impact factor: 7.640

7.  The ALERT-B questionnaire: A screening tool for the detection of gastroenterological late effects after radiotherapy for prostate cancer.

Authors:  D J J Farnell; J Staffurth; S Sivell; S Ahmedzai; J Andreyev; J Green; D S Sanders; C J Ferguson; S Pickett; A Muls; R O'Shea; S H Campbell; S E Taylor; A Nelson
Journal:  Clin Transl Radiat Oncol       Date:  2020-02-04

8.  eRAPID electronic patient self-Reporting of Adverse-events: Patient Information and aDvice: a pilot study protocol in pelvic radiotherapy.

Authors:  Patricia Holch; Simon Pini; Ann M Henry; Susan Davidson; Jacki Routledge; Julia Brown; Kate Absolom; Alexandra Gilbert; Kevin Franks; Claire Hulme; Carolyn Morris; Galina Velikova
Journal:  Pilot Feasibility Stud       Date:  2018-06-05

9.  A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort.

Authors:  Michela Carlotta Massi; Francesca Gasperoni; Francesca Ieva; Anna Maria Paganoni; Paolo Zunino; Andrea Manzoni; Nicola Rares Franco; Liv Veldeman; Piet Ost; Valérie Fonteyne; Christopher J Talbot; Tim Rattay; Adam Webb; Paul R Symonds; Kerstie Johnson; Maarten Lambrecht; Karin Haustermans; Gert De Meerleer; Dirk de Ruysscher; Ben Vanneste; Evert Van Limbergen; Ananya Choudhury; Rebecca M Elliott; Elena Sperk; Carsten Herskind; Marlon R Veldwijk; Barbara Avuzzi; Tommaso Giandini; Riccardo Valdagni; Alessandro Cicchetti; David Azria; Marie-Pierre Farcy Jacquet; Barry S Rosenstein; Richard G Stock; Kayla Collado; Ana Vega; Miguel Elías Aguado-Barrera; Patricia Calvo; Alison M Dunning; Laura Fachal; Sarah L Kerns; Debbie Payne; Jenny Chang-Claude; Petra Seibold; Catharine M L West; Tiziana Rancati
Journal:  Front Oncol       Date:  2020-10-15       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.